Kristin N. Grimsrud, Ph.D. - US grants
Affiliations: | 2012 | Pharmacology and Toxicology | University of California, Davis, Davis, CA |
Area:
Pharmacology, Veterinary Science BiologyWe are testing a new system for linking grants to scientists.
The funding information displayed below comes from the NIH Research Portfolio Online Reporting Tools and the NSF Award Database.The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please sign in and mark grants as correct or incorrect matches.
High-probability grants
According to our matching algorithm, Kristin N. Grimsrud is the likely recipient of the following grants.| Years | Recipients | Code | Title / Keywords | Matching score |
|---|---|---|---|---|
| 2017 | Grimsrud, Kristin | U42Activity Code Description: To develop and support animal (mammalian and nonmammalian) model, or animal or biological materials resources available to all qualified investigators without regard to the scientific disciplines or disease orientations of their research activities or specifically directed to a categorical program. Nonmammalian resources include nonmammalian vertebrates, invertebrates, cell systems, and nonbiological systems. |
Animal Research Infrastructure Improvements @ University of California At Davis Abstract To better support the needs of our aging vivarium, the Mutant Mouse Resource and Research Center at the University of California, Davis (MMRRC-UCD) is driven to improve the infrastructure and equipment within our M3 high-level rodent barrier facility. As a premier distributor of mutant mouse models, the infrastructure of our barrier is a critical factor influencing the health and well-being of the animals we produce and distribute worldwide, currently serving 41 countries. The MMRRC-UCD is the largest center of the four NIH-funded consortiums, and specializes in the cryopreservation and distribution of valuable mutant mouse models. In continued efforts to improve the efficiencies of our operations we have analyzed the deficiencies hindering our optimal production and identified a key factor being aged and outdated equipment. Older animal housing and procedure equipment can lead to increased energy and water use, in addition to excessive noise and vibrations compared to more advanced modernized technologies, all leading to increase stress to the animal. As a result, animal production may be compromised and the costs of operations increased. The laboratory animal community has been strong advocates to promote the ?3R?s? being Replacement, Reduction and Refinement. However, we are now in an era when we must also advocate for what we envision as the ?5E?s?: Efficiencies, Exclusion, Ergonomics, Enrichment, and Education. Our goal is to improve the infrastructure at our barrier facility by implementing lean management principles with an environmentally resourceful emphasis using our innovative 5E?s approach. The current proposal requests funds to upgrade outdated animal transfer stations and biosafety cabinet in the M3 Barrier Facility. Additionally, we will discontinue the use of water bottles as a water source for the animals and convert to using HydropacTM pouches to provide a sterile water source, thus reducing the risk of pathogens and decreasing the environmental resources used. The MMRRC- UCD strives to advantageously integrate innovative concepts for higher efficient, exclusive and ergonomic vivarium designs to transform our standard rodent barrier facility into a state of the art prototype of a Lean- Green animal research facility, to guild other institutions to enable our principles to be applied globally. |
0.915 |
| 2019 — 2021 | Grimsrud, Kristin Nicole | K01Activity Code Description: For support of a scientist, committed to research, in need of both advanced research training and additional experience. |
Characterizing the Impact of Genetic Polymorphism On Fentanyl Efficacy and Tolerance in Pediatrics @ University of California At Davis Project Summary - Kristin Grimsrud, DVM, PhD is a translational veterinary researcher and clinician whose overreaching career goal is to become an expert in pharmacogenetics and development of translational precision animal models. The research she proposes utilizes a unique pediatric burn patient human model to identify genetical polymorphisms impact on opioid metabolism and efficacy Additionally, she proposes to develop a novel rat model possessing the human variant CYP2D6*9, which is known to alter opioid metabolism. Dr. Grimsrud is an Assistant Clinical Professor and the Associate Director the Mouse Biology Program. She completed a combined DVM/PhD specializing in pharmacology and completed a residency in Laboratory Animal Medicine. The proposed career plan will build on her previous training by focusing on multidisciplinary prospective human clinical studies, advanced translational genetics, and mentorship in career development. Dr. Grimsrud has constructed a strong mentoring committee that are world experts in their disciplines. Dr. Tina Palmieri, a burn surgeon and clinical researcher, will be the primary mentor for the proposed mentoring plan. Dr. Palmieri has a Shriner?s Hospital for Children grant to evaluate genetic polymorphisms in pediatric burn patients and their associations to fentanyl efficacy. Dr. Grimsrud will lead the operations of this study for her proposed training. Together with additional secondary mentors and consultants, these experts will provide Dr. Grimsrud with the necessary guidance she needs to become an expert in human clinical research with a focus on opioids, genetics, translational animal models, as well as career development and grantsmanship. Currently little knowledge is known regarding the impact of genetic polymorphisms on fentanyl efficacy in special populations and their influence on opioid tolerance. The proposed research utilizes human and animal models to optimize fentanyl dosing in critical patients. Pediatric burn patients represent the human model due to their need for chronic opioid therapy. Repeated samples will be collected for fentanyl analysis and genotyping, along with evaluating vital parameters and pain scores for assessing efficacy. A novel translational humanized CYP2D6*9 rat model will be developed to use as a tool for pediatric pharmacology studies. Cohorts of CYP2D6*9 humanized pediatric rats will be used for chronic fentanyl administration studies to evaluate alterations in kinetics, efficacy and tolerance. Physiological based pharmacokinetic models will be developed and used for in silco analysis and extrapolation to humans to validate this model and develop an in silco simulation tool for optimizing fentanyl dosing in humans. These efforts will provide clinicians with evidence-based conclusions to guide precision dosing of opioids and provide researchers with a new animal model that can be utilized in a variety of different pharmacology studies. This award will provide Dr. Grimsrud with the necessary mentoring and research needed to start her path towards becoming a nationally-recognized independent investigator and leader in pharmacogenetics, translational and precision medicine and opioid research. |
1 |